Medication info
Allstatin Tablet 10 mg (Rosuvastatin Calcium)

Allstatin Tablet 10 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium Micronized›10.4mg / 1 tablet
Manufacturer / importer
Myungjin Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201001012 · Approved 2010.01.28 · Insurance code 651903240

Summary

Main use
Treats dyslipidemia, slows the progression of atherosclerosis, and prevents cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 mg daily. 3. Older adults : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medication to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race : Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) Ages 10 to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be individualized for each patient according to the recommended treatment goals. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
Myungjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treats dyslipidemia, slows the progression of atherosclerosis, and prevents cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • cardiovascular disease risk factors
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • early coronary artery disease family history
View approved original text

This medication is used as an adjunct when dietary and exercise measures are insufficient to control primary hypercholesterolemia and mixed hyperlipidemia. It enhances effects when used alongside dietary restrictions or other treatments in patients with homozygous familial hypercholesterolemia. It helps lower total cholesterol and LDL cholesterol levels to target levels in hypercholesterolemic patients, delaying the progression of atherosclerosis. It is also used to reduce cholesterol levels in pediatric patients aged 10 to 17 years who meet certain conditions. It is useful as an adjunct to diet in patients with primary dysbetalipoproteinemia and contributes to lowering the risk of cardiovascular diseases, helping to reduce the risks of stroke, myocardial infarction, and vascular interventions. Overall, this drug is utilized to aid in improving cardiovascular health and managing hypercholesterolemia.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 mg daily. 3. Older adults : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medication to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race : Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) Ages 10 to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be individualized for each patient according to the recommended treatment goals. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Precautions

This medication should not be administered to certain patients. For example, patients who are allergic to this drug, those with severely impaired liver function, those with muscle diseases, and those with severe kidney impairment should not use it. Special caution is required when administering this drug to women who are pregnant, breastfeeding, or of childbearing potential without adequate contraception. If a woman of childbearing potential is considered unlikely to be pregnant, and the risks to the fetus are adequately explained, it may be administered. Patients at high risk for muscle-related side effects, such as those with moderate or severe kidney impairment, hypothyroidism, a family history of hereditary muscle disorders, those with alcohol dependency, Asian patients, and those taking certain drugs in combination should have their dosage adjusted or use of the drug contraindicated. This drug contains lactose and should not be given to patients with lactose intolerance or related genetic disorders. While taking this medication, liver function tests should be regularly conducted to monitor for abnormal increases in liver enzyme levels, particularly in patients with a history of excessive alcohol consumption or liver disease. If symptoms such as muscle pain, weakness, or cramps occur, notify medical staff immediately, and if necessary, check creatine kinase levels to assess for significant muscle damage. This drug may increase blood concentration, heightening the risk of muscle damage when taken with other specific medications, so always discuss with medical personnel about other medications being taken. If pregnant or breastfeeding, this drug should not be used, and women of childbearing potential must use appropriate contraception. In the case of overdose, there is no specific antidote; therefore, treatment should be symptom-based, and monitoring for liver function and muscle damage indicators is essential. Lastly, this drug is not known to significantly impair driving or operating machinery, but caution is advised as dizziness may occur.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, peripheral neuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculomotor paralysis, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, hepatic failure, cognitive impairment, ALT elevation, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain storage temperature between 1 degree Celsius and 30 degrees Celsius at room temperature. Proper storage will help ensure drug efficacy.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.